Program
tipiracil
Its studies are mostly in Colorectal Neoplasms, led by Simcere Pharmaceutical Group.
Drug pageTipiracil: every studyAll 6 studies of it, academic ones too, with its approvals, label and forms.Furthest: phase 3, since Sep 30, 20251 company-led study, 1 open or runningNext primary completion: Jan 2028 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Simcere Pharmaceutical Group | 11 open or running | phase 3since Sep 30, 2025 | Sep 30, 2025 | Jan 2028phase 3 · NCT07361003 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 30, 2025First study: phase 3 study in Colorectal NeoplasmsFirst studyNCT07361003 · 464 planned · China
Ahead
- Jan 2028Primary completion: phase 3 study in Colorectal NeoplasmsNCT07361003
TargetBeta
TYMP →read by rule
“Thymidine phosphorylase inhibitor”ChEMBL 37, by rule
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07361003Colorectal Neoplasms · China | 3 | Recruiting | Jan 2028 | 464 |
How it is read
Names in the registry
- “Suvemcitug injection, trifluridine/tipiracil tablets”, 1 entry
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.